Kajetany, Poland Clinical Trials

A listing of Kajetany, Poland clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 105 clinical trials
Featured trial
Pain Sensitivity and Unpleasantness in People with Alzheimer’s Disease and/or Cancer

The University of Tennessee Health Science Center in Memphis, TN has a research opportunity for people to participate in the study: Pain Sensitivity and Unpleasantness in People with Alzheimer’s Disease and Cancer. Specifically, they are looking for individuals over the age of 60 for 1 of 3 groups: (1) those …

cancer
Online studies
primary cancer
AIDS
University of Tennessee Health Science Center
(online study) Contact site
  • 41 views
  • 28 Sep, 2022
  • 1 location
  • Online study
Featured trial
ARE YOU CARING FOR A LOVED ONE WITH DEMENTIA OR MCI?

You may be eligible to participate in a research study evaluating the effects of a new in-hometechnology system for caregivers of people with dementia or mild cognitive impairment. Thestudy is being conducted by Dr. Robert Levenson (University of California, Berkeley,Department of Psychology) and Gene Wang (People Power Company of Care …

cognitive impairment
Accepts healthy volunteers
mild cognitive impairment
dementia
Online studies
University of California, Berkeley
(online study) Contact site
  • 48 views
  • 05 Dec, 2022
  • 1 location
  • Online study
Featured trial
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

recurrent non-small cell lung cancer
refractory non-small cell lung cancer
metastatic non-small cell lung cancer
lung metastases
KRAS
Mirati Research Site
 (9.8 away) Contact site
  • 37 views
  • 02 Dec, 2022
  • +197 other locations
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with endocrine therapy of physician's choice in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy
 (9.9 away) Contact site
  • 21 views
  • 15 Oct, 2022
  • +653 other locations
KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab in Combination With Chemotherapy in Treatment-Naive Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) PLUS chemotherapy in combination with vibostolimab (MK-7684), MK-5890, or MK-4830 in treatment-naïve participants with advanced squamous or non-squamous NSCLC. This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol …

pemetrexed
targeted therapy
stage iv non-small cell lung cancer
mk-3475
carboplatin/paclitaxel
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier
 (9.9 away) Contact site
  • 15 views
  • 17 Oct, 2022
  • +35 other locations
KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Anti-PD-(L)1 Therapy

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with MK-5890 or MK-4830 in participants with advanced squamous or non-squamous NSCLC that have been previously treated with anti-PD-L1 therapy. This study is one of three pembrolizumab substudies being conducted under one pembrolizumab …

targeted therapy
mk-3475
platinum doublet
cancer chemotherapy
progressive disease
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier
 (9.9 away) Contact site
  • 95 views
  • 18 Oct, 2022
  • +35 other locations
KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Treatment Naïve Patients With PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC)

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with MK-4830 in treatment-naïve participants with advanced squamous or non-squamous NSCLC that is PD-L1 positive. This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01). The …

mk-3475
pembrolizumab
lung carcinoma
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier
 (9.9 away) Contact site
  • 1 views
  • 19 Oct, 2022
  • +33 other locations
A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (STAR)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.

psoriasis
apremilast
DMARD
biological drug
NSAID
NZOZ Lecznica MAK-MED. S.C.
 (0.3 away) Contact site
  • 113 views
  • 24 Oct, 2022
  • +97 other locations
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (PAPILLON)

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.

pemetrexed
measurable disease
epidermal growth factor receptor
epidermal growth factor
growth factor
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy
 (9.9 away) Contact site
  • 37 views
  • 21 Oct, 2022
  • +199 other locations
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects With KRASG12C Mutant Advanced Solid Tumors

This is a study evaluating the efficacy, safety, and pharmacokinetics of MK-1084 in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation and MK-1084 plus pembrolizumab in participants with first line (1L) non-small cell lung cancer (NSCLSC) with identified KRASG12C mutation.

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 0170
 (9.9 away) Contact site
  • 2 views
  • 21 Oct, 2022
  • +30 other locations